MDCX · Medicus Pharma Ltd. · Financials
$0.16
-0.01 (-4.67%)
At close · Sep 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$10.27M
Shares
63.18M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$47.28M
-323.8%
FY2025
Diluted EPS
-$2.74
-136.2%
FY2025
Operating Cash Flow
-$22.78M
-122.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | -$197.38K | $25.39K | — | |
| $11.89M | $7.72M | $3.53M | $193.58K | |
| $22.69M | $17.92M | $7.65M | $4.54M | |
| $43.29M | $34.36M | $11.18M | $4.73M | |
| -$43.29M | -$34.36M | -$11.18M | -$4.73M | |
| -$1.6M | -$1.09M | $25.39K | -$584.82K | |
| — | $0 | $0 | $0 | |
| -$56.66M | -$47.28M | -$11.16M | -$5.31M | |
| -$67.04K | -$146 | $0 | — | |
| -$51.22M | -$47.28M | -$11.16M | -$5.31M | |
| -$56.7M | -$47.29M | -$11.16M | — | |
| USD/shares | -$2.41 | -$2.74 | -$1.16 | -$1.53 |
| USD/shares | -$2.41 | -$2.74 | -$1.16 | -$1.53 |
| shares | — | 17.28M | 9.62M | 3.48M |
| shares | — | 17.28M | 9.62M | 3.48M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - General median 6.27×
EV/EBIT
—
P/E (TTM)
—
Drug Manufacturers - General median 33.66×